NASDAQ:AKRO Akero Therapeutics (AKRO) Stock Price, News & Analysis → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free AKRO Stock Alerts $18.82 +0.51 (+2.79%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$18.16▼$19.0650-Day Range$18.31▼$25.2652-Week Range$11.25▼$58.38Volume729,467 shsAverage Volume615,468 shsMarket Capitalization$1.30 billionP/E RatioN/ADividend YieldN/APrice Target$41.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Akero Therapeutics alerts: Email Address Akero Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside118.5% Upside$41.13 Price TargetShort InterestBearish12.05% of Shares Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.36Based on 11 Articles This WeekInsider TradingSelling Shares$3.42 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.87) to ($4.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.19 out of 5 starsMedical Sector176th out of 928 stocksPharmaceutical Preparations Industry71st out of 437 stocks 4.4 Analyst's Opinion Consensus RatingAkero Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAkero Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Akero Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.05% of the outstanding shares of Akero Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkero Therapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Akero Therapeutics has recently decreased by 3.14%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAkero Therapeutics does not currently pay a dividend.Dividend GrowthAkero Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkero Therapeutics has received a 75.57% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akero Therapeutics is -0.75. Previous Next 3.0 News and Social Media Coverage News SentimentAkero Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Akero Therapeutics this week, compared to 5 articles on an average week.Search Interest2 people have searched for AKRO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,420,627.00 in company stock.Percentage Held by InsidersOnly 7.94% of the stock of Akero Therapeutics is held by insiders.Read more about Akero Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Akero Therapeutics are expected to decrease in the coming year, from ($3.87) to ($4.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akero Therapeutics is -5.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akero Therapeutics is -5.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkero Therapeutics has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Akero Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” About Akero Therapeutics Stock (NASDAQ:AKRO)Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Read More AKRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKRO Stock News HeadlinesMay 3, 2024 | insidertrades.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $100,750.00 in StockMay 31 at 10:45 PM | prnewswire.comAKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKROMay 31 at 8:16 PM | businesswire.comKessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Akero Therapeutics, Inc. (AKRO)May 31 at 10:55 AM | prnewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero TherapeuticsMay 30 at 3:45 PM | prnewswire.comAKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud LawsuitMay 30 at 3:11 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKROMay 29, 2024 | prnewswire.comROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKROMay 29, 2024 | globenewswire.comAkero Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 29, 2024 | ca.finance.yahoo.comAKRO Dec 2024 20.000 putMay 27, 2024 | stockhouse.comAKRO SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit!May 24, 2024 | prnewswire.comAKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKROMay 24, 2024 | prnewswire.comAKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud LawsuitMay 22, 2024 | prnewswire.comROSEN, A RANKED AND LEADING FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKROMay 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKROMay 22, 2024 | prnewswire.comAKRO Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Akero Therapeutics, Inc. Shareholders of Deadline in Securities Fraud Class Action LawsuitMay 21, 2024 | stockhouse.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero TherapeuticsMay 21, 2024 | businesswire.comAKRO EQUITY ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKROMay 21, 2024 | prnewswire.comAKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud LawsuitMay 19, 2024 | prnewswire.comAKRO Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges Akero Therapeutics, Inc. Investors with Losses to Contact the FirmMay 18, 2024 | stockhouse.comClass Action Announcement for Akero Therapeutics, Inc. (AKRO): A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc.May 17, 2024 | prnewswire.comAKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKROMay 16, 2024 | prnewswire.comAKRO Investors: Reminder - Important Deadline in Securities Fraud Class Action Lawsuit Akero Therapeutics, Inc.May 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKROMay 16, 2024 | prnewswire.comAKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud LawsuitMay 14, 2024 | prnewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKROSee More Headlines Receive AKRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today6/01/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AKRO CUSIPN/A CIK1744659 Webwww.akerotx.com Phone(650) 487-6488FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$41.13 High Stock Price Target$56.00 Low Stock Price Target$30.00 Potential Upside/Downside+118.5%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-27.72% Return on Assets-25.63% Debt Debt-to-Equity Ratio0.04 Current Ratio30.12 Quick Ratio30.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.24 per share Price / Book1.54Miscellaneous Outstanding Shares69,150,000Free Float63,660,000Market Cap$1.30 billion OptionableOptionable Beta-0.29 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Andrew Cheng M.D. (Age 57)Ph.D., President, CEO & Director Comp: $1.04MDr. Jonathan M. Young J.D. (Age 54)Ph.D., Co-Founder, Executive VP, COO & Secretary Comp: $672.35kDr. Timothy Rolph (Age 70)Co-Founder & Chief Scientific Officer Comp: $722.32kMr. William R. White J.D. (Age 51)Executive VP, CFO, Treasurer & Head of Corporate Development Comp: $678.06kMs. Catriona Yale (Age 52)Executive VP & Chief Development Officer Comp: $678.06kMr. Scott A. Gangloff (Age 50)Chief Technical Officer Mr. David West J.D.Vice President of LegalMr. John J. Schembri (Age 62)Vice President & Head of Finance Mr. Patrick Lamy (Age 51)Senior Vice President of Commercial Strategy More ExecutivesKey CompetitorsAlbireo PharmaNASDAQ:ALBOEnanta PharmaceuticalsNASDAQ:ENTACymaBay TherapeuticsNASDAQ:CBAYBridgeBio PharmaNASDAQ:BBIOGrifolsNASDAQ:GRFSView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckyBought 6,590 shares on 5/28/2024Ownership: 0.041%Virtu Financial LLCBought 10,692 shares on 5/20/2024Ownership: 0.015%Walleye Trading LLCSold 4,300 shares on 5/17/2024Ownership: 0.000%Redmile Group LLCBought 749,226 shares on 5/16/2024Ownership: 2.688%California State Teachers Retirement SystemBought 6,113 shares on 5/16/2024Ownership: 0.078%View All Insider TransactionsView All Institutional Transactions AKRO Stock Analysis - Frequently Asked Questions Should I buy or sell Akero Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AKRO shares. View AKRO analyst ratings or view top-rated stocks. What is Akero Therapeutics' stock price target for 2024? 8 analysts have issued 12 month price objectives for Akero Therapeutics' stock. Their AKRO share price targets range from $30.00 to $56.00. On average, they predict the company's stock price to reach $41.13 in the next year. This suggests a possible upside of 118.5% from the stock's current price. View analysts price targets for AKRO or view top-rated stocks among Wall Street analysts. How have AKRO shares performed in 2024? Akero Therapeutics' stock was trading at $23.35 on January 1st, 2024. Since then, AKRO stock has decreased by 19.4% and is now trading at $18.82. View the best growth stocks for 2024 here. When is Akero Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our AKRO earnings forecast. How were Akero Therapeutics' earnings last quarter? Akero Therapeutics, Inc. (NASDAQ:AKRO) released its quarterly earnings results on Friday, May, 10th. The company reported ($0.90) EPS for the quarter, hitting the consensus estimate of ($0.90). What ETFs hold Akero Therapeutics' stock? ETFs with the largest weight of Akero Therapeutics (NASDAQ:AKRO) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Tema Cardiovascular and Metabolics ETF (HRTS) and Simplify Health Care ETF (PINK) and What other stocks do shareholders of Akero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS). When did Akero Therapeutics IPO? Akero Therapeutics (AKRO) raised $75 million in an IPO on Thursday, June 20th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Akero Therapeutics' major shareholders? Akero Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (8.85%), Price T Rowe Associates Inc. MD (5.87%), Vanguard Group Inc. (5.31%), Baker BROS. Advisors LP (3.92%), Redmile Group LLC (2.69%) and Yiheng Capital Management L.P. (2.07%). Insiders that own company stock include Andrew Cheng, Catriona Yale, G Walmsley Graham, Jonathan Young, Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J Heyman and William Richard White. View institutional ownership trends. How do I buy shares of Akero Therapeutics? Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKRO) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
